Presentation on the Manufacture of Highly Potent Oral Solid-Dosage Forms

October 9, 2018

At CPhI Worldwide 2018, Tom Wilson, vice president of Contract Manufacturing Operations for Pfizer Global Supply and Pfizer CentreOne Contract Manufacturing, will discuss best practices for meeting manufacturing challenges of compliance as requirements shift.

As drugs in development become more potent, regulatory expectations change, forcing manufacturers to adapt.

Tom Wilson, vice president of Contract Manufacturing Operations for Pfizer Global Supply and Pfizer CentreOne Contract Manufacturing, will discuss best practices for meeting the challenges of compliance as requirements shift using Pfizer’s Newbridge, Ireland, facility as a model.

As vice president of Contract Manufacturing Operations for Pfizer Global Supply (PGS) and Pfizer CentreOne Contract Manufacturing, Wilson serves as manufacturing liaison between the two organizations. In previous roles, he led Pfizer Optionality Program for PGS, as well as the integration team for Hospira Device Operations; oversaw management of Pfizer’s Alliance External Suppliers worldwide; and provided counsel on Pfizer’s global manufacturing strategy. He joined Pfizer in 2010 with the acquisition of Wyeth, where he was vice president of Product Operations.

This insight briefing will take place at CPhI Worldwide in Madrid, Spain, on Wednesday, Oct. 10, 2018, 1:10pm–1:40pm at the ICSE Theatre, Hall 1, stand 1G90.

Source: CPhI